Janux Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Janux Therapeutics Inc 's ROA in the second quarter of 2026?
Janux Therapeutics Inc recorded a cumulative net loss of $-103 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -10.13%.

However, within the Healthcare sector 293 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3236, from total ROA ranking in the first quarter of 2026 at 3789.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	0.02 %	-0.49 %	-4.02 %	48.72 %	50.88 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-103	-114	-114	-102	-106
Return On Assets (TTM)	-10.13 %	-11.3 %	-11.2 %	-9.94 %	-11.21 %
JANX's Total Ranking	# 3236	# 3789	# 3280	# 3341	# 3271
Total Assets (TTM) in million	1,015	1,028	1,002	1,006	1,015
Seq. Total Assets Change	-1.25 %	2.66 %	-0.48 %	-0.87 %	-1.75 %
Seq. Net Income Change	-	-	-	-	-

JANX's 5 Years Annual ROA >> Back to JANX Management Effectiveness >> Compare JANX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 101
Sector	# 294
Overall	# 3167

Return On Assets Statistics
High	Average	Low
-3.49 %	-11.46 %	-18.89 %
(Mar 31 2022)		(Jun 30 2023)

Financial Statements
Janux Therapeutics Inc 's Assets	$ 1,015 million	JANX's Balance sheet
Janux Therapeutics Inc 's Income	$ -22 million	Quarterly JANX's Income Statement
JANX's Income by Division		See JANX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-4.02 %	189.67 %	5.17 %	-9.73 %	-
Total Assets in million	1,002	1,044	360	343	379
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-114	-69	-58	-63	-33
Annual Return On Assets	-11.34 %	-6.61 %	-16.18 %	-18.41 %	-8.61 %

JANX's 5 Years Annual ROA >> Back to JANX Management Effectiveness >> Compare JANX ROA to its Competitors

More Return On Assets Ratios
JANX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
JANX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for JANX's Competitors
Subscribers only: Roa for Janux Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for JANX's Customers

You may also want to know
JANX's Roi	JANX's Inventory Turnover Ratio	JANX's Growth Rates	JANX's Dividend Comparisons
	JANX's Profitability Ratios	JANX's Asset Turnover Ratio	JANX's Dividend Growth
JANX's Roe	JANX's Valuation Ratios	JANX's Financial Strength Ratios	JANX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:19:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.